<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844726</url>
  </required_header>
  <id_info>
    <org_study_id>STU77430</org_study_id>
    <nct_id>NCT01844726</nct_id>
  </id_info>
  <brief_title>Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness</brief_title>
  <official_title>Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13,&#xD;
      an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness&#xD;
      on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a single blind randomized parallel group design, we will evaluate the whether a single&#xD;
      dose of GLYX-13 vs. placebo increases cognitive performance on tasks of learning, declarative&#xD;
      memory, and working memory, and associated task-related increases in BOLD activation in&#xD;
      hippocampus and dorsolateral prefrontal cortex, respectively. Positive findings will provide&#xD;
      biomarker evidence for GLYX-13 effects on neural systems underlying these cognitive&#xD;
      processes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Enhanced neural activation underlying episodic learning, declarative memory, and working memory performance</measure>
    <time_frame>within 1 hour of administration</time_frame>
    <description>Evidence of enhanced fMRI BOLD signal change during learning, declarative memory, and working memory tasks among individuals receiving GLYX-13 administration compared to those receiving placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Persistence of enhanced learning, declarative memory, and working memory behavioral performance</measure>
    <time_frame>within 1 week of administration</time_frame>
    <description>Evidence of persistence of enhanced learning, declarative memory, and working memory behavioral performance among individuals receiving GLYX-13 administration compared to those receiving placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episodic learning, declarative memory, and working memory behavioral performance</measure>
    <time_frame>within 1 hour of administration</time_frame>
    <description>Evidence of enhanced learning, declarative memory, and working memory performance among individuals receiving GLYX-13 administration compared to those receiving placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Learning and Memory in Healthy Individuals and Those With Psychiatric Illness</condition>
  <arm_group>
    <arm_group_label>GLYX-13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single IV infusion of GLYX-13, 5mg/kg,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single IV administration of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLYX-13</intervention_name>
    <description>Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist</description>
    <arm_group_label>GLYX-13</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single injection of placebo (saline)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For all Individuals&#xD;
&#xD;
          -  Male and female subjects&#xD;
&#xD;
          -  Ages 18 - 40 years&#xD;
&#xD;
          -  General intellectual abilities falling broadly within the average range (estimated IQ&#xD;
             between 80 - 119)&#xD;
&#xD;
          -  Sufficient ability to understand study requirements and provide written informed&#xD;
             consent&#xD;
&#xD;
        For Patients&#xD;
&#xD;
        -Diagnosis of Schizophrenia or Schizoaffective Disorder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For all individuals:&#xD;
&#xD;
          -  History of neurologic disorder or systemic medical condition that may interfere with&#xD;
             central nervous system function&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  History of heard injury with loss of consciousness or concussion&#xD;
&#xD;
          -  Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid, or&#xD;
             other agent that is being abused in the opinion of the investigator&#xD;
&#xD;
          -  Females who are currently pregnant or plan to become pregnant during the study period&#xD;
&#xD;
          -  History of allergy, sensitivity, or intolerance to N-methyl-D-Aspartate receptor&#xD;
             (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone,&#xD;
             dextropropoxyphene, or ketobemidone&#xD;
&#xD;
          -  History of any ferromagnetic object in the body&#xD;
&#xD;
          -  Presence of any medical device or implant for which MRI is contraindicated including&#xD;
             cardiac pacemaker, aneurysm clip, cochlear implant, copper intrauterine device (IUD),&#xD;
             neurostimulator, or any other device deemed unsafe&#xD;
&#xD;
          -  Bullet or shrapnel in body&#xD;
&#xD;
          -  Metallic braces or permanent retainer&#xD;
&#xD;
          -  Significant claustrophobia&#xD;
&#xD;
        For Healthy Individuals&#xD;
&#xD;
          -  Personal history of any Axis I disorder according to SCID criteria&#xD;
&#xD;
          -  History of treatment with antidepressant, antipsychotic, stimulant,sedative/ hypnotic,&#xD;
             mood stabilizing, or anticholinergic medications or lithium&#xD;
&#xD;
          -  History among first-degree family members of any psychotic illness or major mood&#xD;
             disorder (e.g., major depressive disorder, recurrent; bipolar I or II disorder)&#xD;
&#xD;
        For Patients&#xD;
&#xD;
          -  Treatment with Clozaril&#xD;
&#xD;
          -  Change in medication within 1 month&#xD;
&#xD;
          -  Hospitalization within 1 month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James L Reilly, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>James Reilly</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>healthy individuals</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>schizoaffective disorder</keyword>
  <keyword>learning</keyword>
  <keyword>memory</keyword>
  <keyword>cognitive enhancement</keyword>
  <keyword>fMRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

